首页> 美国卫生研究院文献>Clinical Proteomics >Development of protein biomarkers in cerebrospinal fluid for secondary progressive multiple sclerosis using selected reaction monitoring mass spectrometry (SRM-MS)
【2h】

Development of protein biomarkers in cerebrospinal fluid for secondary progressive multiple sclerosis using selected reaction monitoring mass spectrometry (SRM-MS)

机译:使用选定的反应监测质谱仪(SRM-MS)开发用于继发进行性多发性硬化的脑脊液中的蛋白质生物标记物

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundMultiple sclerosis (MS) is a chronic inflammatory disorder of the central nervous system (CNS). It involves damage to the myelin sheath surrounding axons and to the axons themselves. MS most often presents with a series of relapses and remissions but then evolves over a variable period of time into a slowly progressive form of neurological dysfunction termed secondary progressive MS (SPMS). The reasons for this change in clinical presentation are unclear. The absence of a diagnostic marker means that there is a lag time of several years before the diagnosis of SPMS can be established. At the same time, understanding the mechanisms that underlie SPMS is critical to the development of rational therapies for this untreatable stage of the disease.
机译:背景多发性硬化症(MS)是中枢神经系统(CNS)的慢性炎症性疾病。它涉及到破坏轴突周围的髓鞘和轴突本身。 MS最常出现一系列复发和缓解,但随后在可变的时间内演变为缓慢进展的神经功能障碍形式,称为继发进行性MS(SPMS)。临床表现改变的原因尚不清楚。没有诊断标记意味着可以确定SPMS的诊断存在数年的滞后时间。同时,了解SPMS的基本机制对于开发这种无法治愈的疾病的合理疗法至关重要。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号